Kinase inhibitors
US8383825B2 · kind B2 · utility
0Cited by
0References
30Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 7, 2011 |
| Grant date | Feb 26, 2013 |
| Priority date | — |
| Expiry date | Jul 7, 2031 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to drug delivery systems comprising ocular implant, which include organic molecules, capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation, in combination with a polymer, which polymer serves to control, modify, modulate and/or slow the release of the therapeutic component into the environment of the eye in which said composite is placed.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.